1 in 4 Army Men Have Low T; GLP-1 in Menopause; Retatrutide Side Effects on Reddit
(MedPage Today) -- Roughly a quarter of active-duty U.S. Army men had a single morning testosterone concentration under 300 ng/dL, a commonly used cutoff for low testosterone. (JAMA) Nearly half of American women ages 40 to 60 reported menopausal...
Recent studies reveal concerning findings on the health of U.S. military personnel and the population at large. Approximately one in four active-duty Army men have low testosterone levels, defined as a single morning testosterone concentration below 300 ng/dL, according to a JAMA report. The CDC found that nearly half of American women aged 40 to 60 experience menopausal symptoms, with 15.6% of them using prescription medications to alleviate these issues, as reported in 2025.
Additionally, one in six adults with type 1 diabetes reported moderate to severe depression or anxiety symptoms, as shown in data from the National Health Interview Survey. Researchers have discovered that GLP-1 receptor agonists and emerging multi-hormone receptor modulators can lead to greater weight loss and substantial reductions in blood pressure, as indicated by a meta-analysis of phase III trial data in eClinicalMedicine.
Early research also hints at the potential anti-aging benefits of GLP-1 agonists, as suggested by CNN. Furthermore, Novo Nordisk's investigational combination of semaglutide and cagrilintide has shown promising results, with women in a phase III trial experiencing an average 25% weight loss, regardless of their menopausal stage, according to post-hoc analyses.
Walmart has announced it will cover over 250 prescription drugs, including some insulins and GLP-1 drugs for diabetes, at no cost for its employees in 2027, as reported by CNBC. A Reddit analysis of users who have taken the unapproved weight-loss drug retatrutide revealed that the most frequently cited adverse events included increased appetite, fatigue, increased energy, insomnia, elevated heart rate, and muscle-related issues.
Verdiva Bio recently discontinued a phase II study of a once-weekly oral GLP-1 drug candidate, citing market evolution, as mentioned in FierceBiotech. Additionally, Zealand Pharma and Generate Biomedicines have partnered to utilize artificial intelligence in the development of novel protein-based therapies for obesity and metabolic diseases.
Written by urgent.news from MedPage Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
